349 related articles for article (PubMed ID: 27017616)
1. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
[TBL] [Abstract][Full Text] [Related]
5. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract][Full Text] [Related]
6. Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Yonesaka K; Hirotani K; von Pawel J; Dediu M; Chen S; Copigneaux C; Nakagawa K
Lung Cancer; 2017 Mar; 105():1-6. PubMed ID: 28236978
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
13. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
[TBL] [Abstract][Full Text] [Related]
15. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
Alifrangis L; Schoemaker R; Skartved NJ; Hald R; Montagut C; Kopetz S; Tabernero J; Kragh M; Wade JR
J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):5-18. PubMed ID: 31679083
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
Wakui H; Yamamoto N; Nakamichi S; Tamura Y; Nokihara H; Yamada Y; Tamura T
Cancer Chemother Pharmacol; 2014 Mar; 73(3):511-6. PubMed ID: 24442032
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
